Affiliation:
1. The Second Hospital of Lanzhou University, Lanzhou, China
2. Gansu Province Key Laboratory of Environmental Oncology, China
3. Gansu Province Key Laboratory of Environmental Oncology, Lanzhou, China
4. No. 82, Cuiyingmen, Chengguan, Lanzhou 730030, China
Abstract
In recent years, with the continuous development of molecular immunology, immune checkpoint inhibitors (ICIs) have also been widely used in the treatment of gastric cancer, but they still face some challenges: The first is that only some people can benefit, the second is the treatment-related adverse events (TRAEs) that occur during treatment, and the third is the emergence of varying degrees of drug resistance with long-term use. How to overcome these challenges, combined therapy based on ICIs has become one of the important strategies. This article summarizes the clinical application of ICIs combined with chemotherapy, targeted therapy, radiotherapy, photodynamic therapy, thermotherapy, immune adjuvant, and dual immunotherapy and discusses the mechanism, and also summarizes the advantages and disadvantages of the current combination modalities and the potential research value. The aim of this study is to provide more and more optimized combination regimen for ICI combined therapy in patients with advanced gastric cancer and to provide reference for clinical and scientific research.
Funder
Gansu Province Clinical Research Center for Digestive System Diseases
Project of Gansu Provincial Development and Reform Commission
Major Science and Technology Project of Gansu Province
Project of Gansu Provincial Department of Education
Medical Innovation and Development Project of Lanzhou University
Fundamental Research Funds for the Central Universities of Lanzhou University
Natural Science Foundation of Gansu Province
Medical Research Improvement Project of Lanzhou University